Clinical evaluation of S-1, a new anticancer agent, in patients with advanced gastrointestinal cancer. S-1 Cooperative Gastrointestinal Study Group

Yoshihiko Maehara, K. Sugimachi, M. Kurihara, Tomoaki Taguchi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In developing a new anticancer agent, it is most important to balance the antitumor activity and toxicity of the agent. S-1 was designed to achieve high activity and low toxicity. In it tegafur, a prodrug of 5-FU, is combined with two classes of modulators. CDHP, an inhibitor of 5-FU degradation in the liver, and Oxo, an inhibitor of 5-FU phosphoribosylation in the digestive tract. In both early and late Phase II studies, S-1 was effective against advanced or recurrent gastrointestinal cancer. Toxicities were generally mild, and there were no toxic deaths.

Original languageEnglish
Pages (from-to)476-485
Number of pages10
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume26
Issue number4
Publication statusPublished - Jan 1 1999

Fingerprint

Gastrointestinal Neoplasms
Fluorouracil
Antineoplastic Agents
Tegafur
Poisons
Prodrugs
Gastrointestinal Tract
Liver

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Clinical evaluation of S-1, a new anticancer agent, in patients with advanced gastrointestinal cancer. S-1 Cooperative Gastrointestinal Study Group. / Maehara, Yoshihiko; Sugimachi, K.; Kurihara, M.; Taguchi, Tomoaki.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 26, No. 4, 01.01.1999, p. 476-485.

Research output: Contribution to journalArticle

@article{1455904c8dc0452c82b4a8a174959f99,
title = "Clinical evaluation of S-1, a new anticancer agent, in patients with advanced gastrointestinal cancer. S-1 Cooperative Gastrointestinal Study Group",
abstract = "In developing a new anticancer agent, it is most important to balance the antitumor activity and toxicity of the agent. S-1 was designed to achieve high activity and low toxicity. In it tegafur, a prodrug of 5-FU, is combined with two classes of modulators. CDHP, an inhibitor of 5-FU degradation in the liver, and Oxo, an inhibitor of 5-FU phosphoribosylation in the digestive tract. In both early and late Phase II studies, S-1 was effective against advanced or recurrent gastrointestinal cancer. Toxicities were generally mild, and there were no toxic deaths.",
author = "Yoshihiko Maehara and K. Sugimachi and M. Kurihara and Tomoaki Taguchi",
year = "1999",
month = "1",
day = "1",
language = "English",
volume = "26",
pages = "476--485",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "4",

}

TY - JOUR

T1 - Clinical evaluation of S-1, a new anticancer agent, in patients with advanced gastrointestinal cancer. S-1 Cooperative Gastrointestinal Study Group

AU - Maehara, Yoshihiko

AU - Sugimachi, K.

AU - Kurihara, M.

AU - Taguchi, Tomoaki

PY - 1999/1/1

Y1 - 1999/1/1

N2 - In developing a new anticancer agent, it is most important to balance the antitumor activity and toxicity of the agent. S-1 was designed to achieve high activity and low toxicity. In it tegafur, a prodrug of 5-FU, is combined with two classes of modulators. CDHP, an inhibitor of 5-FU degradation in the liver, and Oxo, an inhibitor of 5-FU phosphoribosylation in the digestive tract. In both early and late Phase II studies, S-1 was effective against advanced or recurrent gastrointestinal cancer. Toxicities were generally mild, and there were no toxic deaths.

AB - In developing a new anticancer agent, it is most important to balance the antitumor activity and toxicity of the agent. S-1 was designed to achieve high activity and low toxicity. In it tegafur, a prodrug of 5-FU, is combined with two classes of modulators. CDHP, an inhibitor of 5-FU degradation in the liver, and Oxo, an inhibitor of 5-FU phosphoribosylation in the digestive tract. In both early and late Phase II studies, S-1 was effective against advanced or recurrent gastrointestinal cancer. Toxicities were generally mild, and there were no toxic deaths.

UR - http://www.scopus.com/inward/record.url?scp=0033087551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033087551&partnerID=8YFLogxK

M3 - Article

C2 - 10097744

AN - SCOPUS:0033087551

VL - 26

SP - 476

EP - 485

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 4

ER -